[Adjuvant chemotherapy for primary breast cancer--review of 1998 St. Gallen's conference].
The 6th International conference on Adjuvant Therapy of Primary Breast Cancer was held in St. Gallen, Switzerland in February 1998, and this is an overview of its guidelines. Since 1995, several specific areas have accumulated important new information and were highlighted at the 1998 conference. These include the following: genetic testing of women at risk; the availability of chemopreventive agents for high-risk and postmenopausal women; changes in diagnostic procedures with an intent to reduce axillary dissection by introducing sentinel-node biopsy; results from trials of preoperative chemotherapy; initiatives to evaluate preoperative endocrine therapies; and debate on the role of increased local control by postmastectomy radiation, its safety and effectiveness. At the conclusion of the Conference, a consensus panel of experts was asked to develop a series of guidelines and recommendations for selection of adjuvant systemic treatments in specific patient populations. The panel reviewed and modified its 1995 guidelines and recommendations based on new evidence that has emerged from clinical research.
Taguchi
T
T
Osaka University, Japan.
D000970:Antineoplastic Agents / Q000008:administration & dosage*; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D003245:Consensus Statements as Topic; D005260:Female; D006801:Humans; D008198:Lymph Nodes / Q000473:pathology; D008207:Lymphatic Metastasis
D000970:Antineoplastic Agents; D018931:Antineoplastic Agents, Hormonal